Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) (GABRA2)

The Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) is a critical component of the pentameric ligand-gated chloride channels that facilitate the majority of fast inhibitory neurotransmission in the mammalian brain (UniProt P47869). These alpha-2-containing subtypes are specifically enriched in the limbic system and are uniquely positioned on the axon initial segments of pyramidal neurons, where they exert powerful control over neuronal output and synchronization (PubMed: 11689594). While the alpha-1 subunit is primarily associated with the sedative and hypnotic effects of benzodiazepines, the alpha-2 subunit is the principal mediator of anxiolytic, anticonvulsant, and muscle-relaxant activities (PubMed: 10842354). This functional distinction makes the alpha-2 subunit a high-priority target for developing subtype-selective positive allosteric modulators (PubMed: 21910647). Such drugs, including clinical candidates like darigabat, aim to treat anxiety, epilepsy, and chronic pain with reduced sedative and cognitive side effects compared to non-selective benzodiazepines (ClinicalTrials.gov: NCT04244175). However, therapeutic development must address challenges such as the potential for tolerance, physical dependence, and abuse associated with GABAergic modulation (PubMed: 12171574). EEG beta-band power is often used as a pharmacodynamic biomarker to monitor the activity of these modulators in clinical settings (PubMed: 25326625). Overall, the alpha-2 subunit represents a refined approach to modulating the GABAergic system for neuropsychiatric and neurological disorders.

Other names

GABA(A) receptor subunit alpha-2GABRA2GABA-A receptor alpha-2Gamma-aminobutyric acid receptor subunit alpha-2

Positive allosteric modulation